EUCTR2020-002037-15-ES
Active, not recruiting
Phase 1
Multicenter, randomized, open-label study to evaluate the efficacy and safety of SOC + Sarilumab versus Standard of Care for the Early Treatment of COVID-19-pneumonia in Hospitalized Patients
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Cristina Avendaño Sola
- Enrollment
- 200
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion Criteria
- •1\.Patients willing to provide written informed consent to participate in this study. Witnessed oral consent will be accepted in order to avoid paper handling. Written consent by patient or representatives will be obtained as soon as possible.
- •2\.The patient is at least 18 years of age.
- •3\.The patient is positive for novel coronavirus by real\-time RT\-PCR
- •4\.The patient is hospitalized for COVID\-19 without either mechanical ventilation (invasive or non\-invasive) or oxygen mask with reservoir bag and at least one of the following:
- •\-Radiographic evidence of pulmonary infiltrates by imaging (chest x\-ray, CT scan, etc.), OR clinical assessment (evidence of rales/crackles on exam)
- •\- AND SpO2 \= 94% on room air that requires supplemental oxygen.
- •5\.More than 7 days between the onset of symptoms (fever, dysnea, and/or cough) and treatment administration day. In the absence of fever, cough, or dyspnea, other symptoms like asthenia, headache, or gastrointestinal symptoms may be considered
- •6\.The patients presents progressive elevation of inflammatory parameters suggestive of a hyperinflammatory syndrome:
- •Presence of elevated IL\-6 (\>40pg/ml)
Exclusion Criteria
- •Exclusion Criteria
- •1\.Requiring mechanical ventilation (invasive or non\-invasive) or oxygen mask with reservoir bag at screening.
- •2\.Participation in any other clinical trial of an experimental treatment for COVID\-19\.
- •3\.In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments.
- •4\.Any incompatibility or allergy to the administration of sarilumab or corticosteroids.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in healthy young female volunteers over a period of 3 treatment cyclescontraceptionFertility controlNL-OMON34076Bayer110
Active, not recruiting
Not Applicable
Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in healthy young female volunteers over a period of 3 treatment cycles - Inhibition of ovulation and pharmacokinetic study of 3 transdermal EE and GSD formulationsPrevention of PregnancyMedDRA version: 12.1Level: LLTClassification code 10060346Term: Transdermal contraceptionEUCTR2010-021255-81-NLBayer HealthCare AG174
Active, not recruiting
Not Applicable
Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in healthy young female volunteers over a period of 3 treatment cycles - Inhibition of ovulation and pharmacokinetic study of 3 transdermal EE and GSD formulationsEUCTR2010-021255-81-DEBayer HealthCare AG174
Active, not recruiting
Not Applicable
Multicenter, open-label, randomized study to evaluate inhibition of ovulation of two transdermal patch formulations containing 0.55 mg ethinylestradiol and either 1.05 or 2.1 mg gestodene in healthy young female volunteers over a period of 3 treatment cycles - Inhibition of ovulation and pharmacokinetics of transdermal EE and GSDThe trial will be performed in healthy female volunteers. The intended indication is femal contraception.EUCTR2009-009177-10-DEBayer HealthCare AG
Active, not recruiting
Phase 1
A randomized, open-label, multicenter study evaluating thrombovascular events in subjects with cancer receiving chemotherapy and administered epoetin alfa once or three times a week for the treatment of anemia.EUCTR2006-000914-19-GBJanssen-Cilag International N.V.